# Practitioner's Docket No. <u>U-011415-0</u>

# **PATENT** IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

•								
	In re application of: John WALKER, et al							
۵	Serial No.: 08/913,430	Froup No.: 1641						
	Filed: September 12, 199	aminer: R. Swartz						
	For: ANTIGEN COMPOSITION AGAIN	ST MYCOPLASMA						
	Assistant Commissioner for Patents Washington, DC 20231							
	AMENDMENT TRANSMITTAL							
	1. Transmitted herewith is an amendment fo	r this application.						
	STA	ATUS						
	2. Applicant is							
	□ a small entity. A statement:							
	☐ is attached.							
	□ was already filed.							
	☑ other than a small entity							
	CERTIFICATE OF MAILING	TRANSMISSION (37 CFR 1.8(a))						
	I hereby certify that, on the date shown below, this correspon							
	MAILING	FACSIMILE						
	deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, DC 20231.	transmitted by facimile to the Patent and Trademark Office.						
	Date: <u>January 28, 1999</u>	Signature						
02/02/19 <del>9</del> 9 AP	МОНАМИЕ 00000121 08913430	CHIFFORD J. MASS						
01 FC:115	110.00 GP	(Type or print name of person certifying)						
		(Amendment Transmittal—page 1 of 4)						

# **EXTENSION OF TERM**

NOTE:	"Extension of Time in Patent Cases (Supplement Amendments) — If a timely and complete response has been filed after a Non-Final Office Action, an extension of time is not required to permit filing and/or entry of an additional amendment after expiration of the shortened statutory period.						
	entry of statutory Notice o	a Notice v period u f Appeal	e has been filed after a Final O of Appeal or filing and/or en nless the timely-filed response has been filed within the shor 5 (1061 O.G. 34-35).	try oj plac	`an additional amend ed the application in c	ment after ex ondition for	xpiration of the shortened allowance. Of course, if a
NOTE:	See 37 CFR 1.645 for extensions of time in interference proceedings, and 37 CFR 1.550(c) for extensions of time is reexamination proceedings.			c) for extensions of time in			
3.	The proceedings herein are for a patent application and the provisions of 37 CFR 1.136 apply			37 CFR 1.136 apply.			
			(complete (a) c	or (b	), as applicable)		
	(a)	×	Applicant petitions for (fees: 37 CFR 1.17(a)(1				
		Extens			for other than		Fee for small entity
	$\boxtimes$	one mo		\$	110.00		\$ 55.00
		two mo	onths	\$	380.00		\$ 190.00
		three n	nonths	\$	870.00		\$ 435.00
		four m	onths	\$ 1	,360.00		\$ 680.00
					Fee: \$110.	00	
If an ac	dditional	extensi	on of time is required, pl	ease	consider this a pe	tition there	efor.
			(check and complete	the r	next item, if applic	able)	
	An extension for months has already been secured. The fee paid therefor of \$ is deducted from the total fee due for the total months of extension n requested.						
	Extension fee due with this request \$						
				OF	1		
	(b)		Applicant believes that tional petition is being inadvertently overlooke	mad	le to provide for tl	ne possibil	ity that applicant has

#### **FEE FOR CLAIMS**

4. The fee for claims (37 CFR 1.16(b)-(d)) has been calculated as shown below:

									OTHER T	HAN
Α	(C	col.1)		(Col. 2)	(Col. 3)	SMALL	ENTITY		SMALL E	NIITY
	Ren	laims nainin After endme	ıg	Highest No. Previously Paid For	Present Extra	Rate	Addit. Fee	OR	Rate	Addit. Fee
Tota	1	*	Minus	**	=	x \$11 =	\$		x \$22 =	\$
Inde	p.	*	Minus	***	=	x \$41 =	\$		x \$82 =	\$
	irst Pres	entatio	on of Mult	iple Depender	nt Claim	+ \$135 =	: \$		+ \$270 =	\$
					· · · ·	Total Addit. Fee	\$	OR	Total Addit. Fee	<b>\$</b>
<ul> <li>** If the "Highest No. Previously Paid For" IN THIS SPACE is less than 20, enter "20".</li> <li>*** If the "Highest No. Previously Paid For" IN THIS SPACE is less than 3, enter "3".         The "Highest No. Previously Paid For" (Total or Indep.) is the highest number found in the appropriate box in Col. 1 of a prior amendment or the number of claims originally filed.     </li> <li>**WARNING: "After final rejection or action (§ 1.113) amendments may be made canceling claims or complying with any requirement of form which has been made." 37 CFR 1.116(a) (emphasis added).</li> </ul>										
				(complete	(c) or (d),	as applicable	e)		·	
	(c)		No a	dditional fee f	or claims i	s required.				
					OR					
	(d)		Tota	l additional fee	e for claim	s required \$.				
				F	EE PAYN	<b>TENT</b>				
5.	⊠□	Ch	arge Acco	check in the sunt Noof this transmit	the s	sum of \$				

### **FEE DEFICIENCY**

NOTE: If there is a fee deficiency and there is no authorization to charge an account, additional fees are necessary to cover the additional time consumed in making up the original deficiency. If the maximum, six-month period has expired before the deficiency is noted and corrected, the application is held abandoned. In those instances where authorization to charge is included, processing delays are encountered in returning the papers to the PTO Finance Branch in order to apply these charges prior to action on the cases. Authorization to charge the deposit account for any fee deficiency should be checked. See the Notice of April 7, 1986, (1065 O.G. 31-33).

6. If any additional extension and/or fee is required, charge Account No. 12-0425.

# AND/OR

If any additional fee for claims is required, charge Account No. 12-0425.

SIGNATURE OF PRACTITIONER

Reg. No. 30,086

Tel. No. (212) 708-1890

Customer No.

LAIFFORD J. MASS

(Type or print name of practitioner)

t/s Ladas & Parry 26 West 61 Street

New York, NY 10023



## Practiti ner's Docket No. U-011415-0

# **PATENT** IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

John W

RECEIVED

Serial No.: 08/913,430

Examiner: R. Swartz

Group No.: 1641

1000

Filed: For:

September 12, 19

INST MYCOPLASMA

**Box Sequence Assistant Commissioner for Patents** Washington, DC 20231

Washington, DC 20231.

# SUBMISSION OF "SEQUENCE LISTING," COMPUTER READABLE COPY, AND/OR AMENDMENT PERTAINING THERETO FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE

#### CERTIFICATION UNDER 37 CFR 1.8(a) and 1.10\*

(When using Express Mail, the Express Mail label number is mandatory; Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

thereon prior to mailing. 37 CFR 1.10(b).

### **MAILING**

deposited with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents,

	37 CFR 1.8(a)	37 CFR 1.10*
	with sufficient postage as first class mail.	☐ /as "Express Mail Post Office to Address"  Mailing Label No (mandatory)
	TRANSMISS	
	transmitted by facsimile to the Patent and Trademark Office.	
Dat	e: January 28, 1999	Signature//
		(Type or print name of person certifying)
*W	ARNING: Each paper or fee filed by "Express Mail" must ha	ve the number of the "Express Mail" mailing label placed

granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

"Since the filing of correspondence under  $\S$  1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be

(Submission-Nucleotide and/or Amino Acid Sequence-page 1 of 6)

## (check and complete this item, if applicable)

This replies to the Office Letter dated December 1, 1998.

NOTE:

If these papers are filed before the office letter issues, adequate identification of the original papers should be made, e.g., in addition to the name of the inventor and title of invention, the filing date based on the "Express Mail" procedure, the serial number from the return post card or the attorney's docket number added.

A copy of the Office Letter is enclosed.

			IDENTIFICA	TION OF PERSON MAKING STATEMENT
2.	<u>I,</u>	Clif	ford J. Mass	
			(Type	or print name of person signing below)
	sta	te th	e following:	
				ITEMS BEING SUBMITTED
3.	Sul	omit	ted herewith is/are	
				(check each item as applicable)
	A.	×	•	for the nucleotide and/or amino acid sequence(s) in this application figures is assigned a separate identifier as required in 37 CFR § 1.821(c) and 1.823.
	В.	⊠		description and/or claims, wherein reference is made to the sequence identifier, as required in 37 CFR § 1.821(d).
	C.	⊠		ence Listing" submitted for this application in computer readable form e requirements of 37 CFR §§ 1.821(e) and 1.824.
	D.			s application, in accordance with 37 CFR § 1.821(e), the computer om applicant's other application identified as follows:
			In re application of: Serial No.: 0 / Filed: For:	Group No.: Examiner:
Ide			omputer readable form )" of the application as	n(s) of applicant's other application corresponds to the "Sequences follows:

Computer Readable Form

"Sequence Identifier"

(other applications)

(this application)

NOTE: "If the computer readable form of a new application is to be identical with the computer readable form of another application of the applicant on file in the Office, reference maybe made to the other application and computer readable form in lieu of filing a duplicate computer readable form in the new application. The new application shall be accompanied by a letter making such reference to the other application and computer readable form, both of which shall be completely identified." 37 CFR 1.821(e).

(Submission-Nucleotide and/or Amino Acid Sequence—page 2 of 6)

	E.	☒	A statement that the content of each "Sequence Listing" submitted and each computer readable copy are the same, as required in 37 CFR § 1.821(g).
			☐ Because the statement is not made by a person registered to practice before the Office, the Statement is verified as required in 37 CFR § 1.821(b).
	F.	⊠	Because this submission is made in fulfilling the requirement under 37 CFR § 1.821(g), a statement that the submission includes no new matter.
			☐ Because the statement is not made by a person registered to practice before the Office, the statement is verified, as required in 37 CFR § 1.821(g).
			STATEMENT THAT "SEQUENCE LISTING" AND COMPUTER READABLE COPY ARE THE SAME AND/OR THAT PAPERS SUBMITTED INCLUDES NO NEW MATTER
4.	I he	ereb	y state:
			(complete applicable item A and/or B)
	A.		Each computer readable form submitted in this application, including those forms requested to be transferred from applicant's other application, is the same as the "Sequence Listing" to which it is indicated to relate.
	В.	⊠	All papers accompanying this submission, or for which a request for transfer from applicants' other application, introduce no new matter.
			STATUS
5.	Аp	plica	ant is
		a si	mall entity. A statement:
			is attached.
			was already filed.
	⊠	oth	ner than a small entity.
			EXTENSION OF TERM
6. NOT	<b>E</b> :		ension of Time in Patent Cases (Supplement Amendments) If a timely and complete response has been filed after a Non-Final Office Action, an usion of time is not required to permit filing and/or entry of an additional amendment after expiration of the shortened statutory period.

If a timely response has been filed after a Final Office Action, an extension of time is required to permit filing and/or entry of a Notice of Appeal or filing and/or entry of an additional amendment after expiration of the shortened statutory period unless the timely-filed response placed the application in condition for allowance. Of course, if a Notice of Appeal has been filed within the shortened statutory period, the period has ceased to run." Notice of Dec. 10, 1985 (1061 O.G. 34-35).

(Submission-Nucleotide and/or Amino Acid Sequence—page 3 of 6)

7. The proceedings herein are for a patent application and the provisions of 37 CFR 1.136 apply.

(complete (a) or (b) as applicable)

(a) ■ Applicant petitions for an extension of time under 37 CFR 1.136 (fees: 37 CFR 1.17(a)(1) (4)) for the total number of months checked below:

	Extension (months)	Fee for other than small entity	Fee for small entity		
×	one month	\$110.00	\$ 55.00		
	two months	\$380.00	\$ 190.00		
	three months	\$870.00	\$ 435.00		
	four months	\$1,360.00	\$ 680.00		

Fee \$ 110.00

If an additional extension of time is required, please consider this a petition therefor.

(check and complete the next item, if applicable)

An extension	n for months has already been secured, and the fee paid therefore
of \$	is deducted from the total fee due for the total months of extension now
requested.	

Extension fee due with this request \$\_\_\_\_\_

#### OR

(b) Applicant believes that no extension of term is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition and fee for extension of time.

## **FEE PAYMENT**

- 8.  $\square$  Attached is a check in the sum of \$110.00.
  - ☐ Charge Account No. <u>12-0425</u> the sum of \$ A duplicate of this transmittal is attached.

# **FEE DEFICIENCY**

NOTE: If there is a fee deficiency and there is no authorization to charge an account, additional fees are necessary to cover the additional time consumed in making up the original deficiency. If the maximum, six-month period has expired before the deficiency is noted and corrected, the application is held abandoned. In those instances where authorization to charge is included, processing delays are encountered in returning the papers to the PTO finance Branch in order to apply these charges prior to action on the cases. Authorization to charge the deposit account for any fee deficiency should be checked. See the Notice of April 7, 1986, 1065 O.G. 31-33.

10. 

✓ If any additional extension and/or fee is required, charge Account No. 12-0425.

(Submission-Nucleotide and/or Amino Acid Sequence—page 4 of 6)

28/16 Date: <u>January 20/1999</u>	SIG	Clifford J. Mass (Type or griff name of person signing statement)  Signature
Clifford J. Mass Reg. No. 30,086 c/o Ladas & Parry 26 West 61 Street New York, NY 10023 Tel. No.: (212) 708-1890		
(If applicable)		Inventor Assignee of complete interest Person authorized to sign on behalf of assignee Attorney or agent record Filed under Rule 34(a) Other  (specify identity of person signing)
	(complete the j	following, if applicable)
(Type name of assignee) Address of assignee		
Title of person authorized to sign on	behalf of assignee	
A "STATEMENT UNDER 37	CFR 3.73(b)" is	s attached.
Assignment recorded in PTO o	on	

(Submission-Nucleotide and/or Amino Acid Sequence—page 5 of 6)

SIGNATURE OF PRACTITIONER
(Type or print name of practitioner)
P.O. Address